在阿尔茨海默氏病中的ABCA7相关的临床特征和分子机制
Xiao-Hang Qian1,2,3, Si-Yue Chen3, Xiao-Li Liu4
1Department of Geriatrics, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Molecular neurobiology
|June 15, 2023
概括
在ATP结合盒载体A7 (ABCA7) 中的遗传变异显著提高了阿尔茨海默病 (AD) 的风险. ABCA7功能障碍影响脂质代谢,粉样蛋白处理和免疫反应,有助于AD的发病.
科学领域:
- 神经退行性疾病的神经退行性疾病
- 阿尔茨海默氏症疾病的遗传学
- 阿尔茨海默病的分子机制
背景情况:
- 阿尔茨海默氏病 (AD) 是一种流行的神经退行性疾病,其致病性尚未完全理解.
- 遗传因素在阿尔茨海默病的表型中起着重要的作用.
- ATP结合盒载体A7 (ABCA7) 是AD的一个关键遗传风险因素.
研究的目的:
- 为了阐明ABCA7变体对阿尔茨海默病 (AD) 病原发生的影响.
- 探索AD中ABCA7变化的功能后果.
- 在AD中识别与ABCA7相关的潜在治疗点.
主要方法:
- 在AD患者中分析各种ABCA7遗传变异 (SNP,突变,拼接).
- 研究ABCA7蛋白表达和结构变化.
- 检查ABCA7在脂质代谢,APP处理和微质功能中的作用.
主要成果:
- ABCA7变种改变了蛋白质功能,影响了脂质代谢,粉样蛋白前体蛋白 (APP) 处理和免疫细胞活性.
- 由于ABCA7缺乏,通过ER压力 (PERK/eIF2α通路) 诱导神经元亡.
- 缺少ABCA7会增加Aβ的产生 (SREBP2/BACE1通路),并影响微质Aβ的清除.
结论:
- ABCA7变种通过破坏包括脂质代谢,APP处理和免疫反应在内的细胞过程,从而导致AD.
- 准ABCA7为阿尔茨海默病提供了潜在的治疗策略.
- 对特定的ABCA7变体和向疗法的进一步研究是有必要的.
相关概念视频
01:26Alzheimer's Disease: Overview
532
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
532
01:22Alzheimer's Disease: Treatment
223
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
223
03:03Amyloid Fibrils
9.6K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
9.6K
01:31ABC Transporters: Exporter
4.4K
ATP-binding cassette or ABC transporter is the largest superfamily of integral membrane proteins. The transporters have transmembrane-binding domains (TMDs) and nucleotide-binding domains (NBDs). The TMDs are specific to their substrates, whereas the NBDs are similar to engines that complete ATP hydrolysis to complete the substrate transport. They can be full transporters consisting of two TMDs and NBDs, half transporters with one TMD and NBD, while some encoded with a single TMD or NBD are...
4.4K